Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension, interstitial lung disease, and renal crisis in SSc patients underlie a high mortality rate. The treatment landscape for SSc is dominated by generics and off-label drugs to treat the wide array of SSc symptoms, with only Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra (tocilizumab) as FDA-approved therapies. This report offers insights from real-world U.S. claims data into prescribing trends in SSc to help emerging players better understand current treatment practices in SSc and how to capitalize on the unmet needs in this underserved population.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
- How have Ofev and Actemra been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SSc patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Key drugs covered: Ofev, Actemra, select other biologics (e.g., rituximab)
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Real-world data: Longitudinal patient-level claims data analysis
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
